REG - AstraZeneca PLC - Publication of a Prospectus

AstraZenecaAnnouncement

22/06/2018 07:05

RNS Number : 2100S
AstraZeneca PLC
22 June 2018
 


 
22 June 2018 07:00 BST
 
Publication of Prospectus
Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:
Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").
 
The last drawdown under the EMTN programme was in 2016.
 
To view the full document, please paste the following URL into the address bar of your browser.
 
http://www.rns-pdf.londonstockexchange.com/rns/2100S_1-2018-6-21.pdf
 
A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:
 
http://www.morningstar.co.uk/uk/NSM
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 




Media Relations


 


 




Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 
 


+44 203 749 5712




Josie Afolabi


 


+44 203 749 5631




Craig Marks


Finance; Fixed Income; M&A


+44 7881 615 764




Henry Wheeler


Oncology


+44 203 749 5797




Mitchell Chan


Oncology; Other


+1 240 477 3771




Christer Gruvris


Brilinta; Diabetes


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free


 


+1 866 381 7277




 


 


 




 


 


 




 


 


 




 


 


 




 
Adrian Kemp

Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PDIFKDDBCBKDKAB